Speciality: Oncology
Description:
Dr. Srinivas K G presents a compelling retrospective analysis titled "ESMO Breast Cancer 2022: P REALITY X" in this insightful video. The discussion delves into the real-world efficacy and clinical outcomes of a specific breast cancer treatment regimen, as examined during the ESMO Breast Cancer 2022 conference. Dr. Srinivas meticulously reviews the data, highlighting key findings, patient responses, and the implications for future therapeutic strategies. His expertise provides valuable perspectives for oncologists and researchers seeking to optimize breast cancer management.
The video explores the retrospective study design, patient demographics, and survival outcomes analyzed in the P REALITY X trial. Dr. Srinivas emphasizes the importance of real-world evidence in complementing randomized clinical trials, offering a more comprehensive understanding of treatment effectiveness in diverse populations. He also addresses potential limitations and biases inherent in retrospective analyses, ensuring a balanced interpretation of the results. This session is a must-watch for medical professionals aiming to stay updated on the latest advancements in breast cancer research.
Dr. Srinivas K G’s detailed breakdown of the P REALITY X study serves as an invaluable resource for the oncology community. By bridging the gap between clinical trials and real-world practice, his analysis fosters a deeper appreciation for evidence-based decision-making. Stay tuned for more expert discussions and cutting-edge insights in upcoming videos. Your journey towards mastering breast cancer therapeutics continues here!
See More Webinars @ Hidoc Webinars
1.
Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
Interleukin-6 may boost prediction of obesity-related cancers
4.
Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.
5.
As EGFR internalization is decreased, BUB1 controls EGFR signaling.
1.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
2.
Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies
3.
HCC Codes in Oncology: Care Optimization in Plexiform Neurofibroma Management
4.
Unraveling the Mysteries of Coagulopathy: A Comprehensive Definition
5.
Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
5.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation